Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority to UY30514ApriorityCriticalpatent/UY30514A1/en
Publication of UY30514A1publicationCriticalpatent/UY30514A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invencion se refiere a un compuesto de la formula: o sales farmacéuticamente aceptables del mismo, y al uso de estos compuestos para el tratamiento de enfermedades proliferativas, tales como cáncer, en mamíferos.The present invention relates to a compound of the formula: or pharmaceutically acceptable salts thereof, and to the use of these compounds for the treatment of proliferative diseases, such as cancer, in mammals.
Use of compounds derived from pyridin-4-yl-benzene-1,4-diamino substituted by alindole to prepare a medicament for the treatment of a proliferative disorder such as cancer.
Compounds derived from phenylamino-isonicotinamide; mek inhibitors; Pharmaceutical composition and use for the treatment of hyperproliferative diseases such as cancer and inflammation.
Compounds derived from 8-oxo-9- [3- (1h-benzimidazol-2-yloxy) -phenyl] -4,5,6,7,8,9-hexahydro-2h-pyrrolo [3,4-b] quinoline Ethyl -3-carboxylate; preparation procedure; pharmaceutical composition comprising it; intermediate compounds; and use of the compound as a selective inhibitor of aurora a and b kinases to treat cancer.
Use of a substituted heterocyclic nitrogen compound for the treatment of cancers such as colon cancer or multiple myeloma; pharmaceutical composition comprising the compound.